Navigation Links
Misonix Announces New Distribution Agreement for The Netherlands
Date:11/5/2008

FARMINGDALE, N.Y., Nov. 5 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of cancer and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with privately-held Eclipse Medical BV, based in Rotterdam, The Netherlands, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne(R) Ultrasonic Wound Debrider. The agreement provides Eclipse Medical with the rights to sell in The Netherlands, and includes minimum purchase requirements.

Eclipse Medical, well known in The Netherlands marketplace as an aggressive competitor, has built a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis on surgery and oncology.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Eclipse Medical's commitments to quality and service to its clinical customers, as well as their track record of successfully introducing high tech medical devices to their market, was quite appealing to Misonix. We are excited about partnering with them and we are particularly pleased that they will be distributing three of our products through their well established distribution network," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at http://www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Misonix Contact: Investor Relations Contact:

Richard Zaremba Cameron Associates, Inc.

631-694-9555 Kevin McGrath

invest@misonix.com 212-245-4577

Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Misonix Announces Interim Distribution Agreement for Italy
2. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
5. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
6. Perrigo Company Announces Dividend Increase
7. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
8. Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation
9. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
10. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
11. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announce that Mitsui & Co. Ltd., its partner in ... plant, is investing an additional CDN$25 million in the ... stake from 30% to 40%.  Mitsui will also play ... produced in Sarnia , providing dedicated ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... today announced that it has joined the Human Vaccines Project, a public-private ... diseases and cancer. , The Human Vaccines Project brings together leading ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, ... Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February ... than 100 tables for its annual event, which will run from 3:00 p.m. ...
(Date:2/10/2016)... Miami, FL (PRWEB) , ... February 10, 2016 ... ... leader in regenerative medicine, has announced a new agreement with Singapore-based Global Stem ... qualified physicians from the Philippines, Thailand and Singapore in the latest adipose and ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/27/2016)... Jan. 27, 2016  Rite Track, Inc. a leading ... West Chester, Ohio announced today the ... staff, based in Austin, Texas , ... to provide modifications, installations and technical support offerings for ... of PLUS, commented, "PLUS has provided world class service ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
Breaking Biology News(10 mins):